Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
about
CMV: Prevention, Diagnosis and TherapyCytomegalovirus antivirals and development of improved animal modelsGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveAntiviral drug resistance of human cytomegalovirus.Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.Current concepts on cytomegalovirus infection after liver transplantationCyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Progress in the development of new therapies for herpesvirus infectionsResistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.The Emerging Roles of Viroporins in ER Stress Response and Autophagy Induction during Virus InfectionHuman cytomegalovirus pUL97 kinase induces global changes in the infected cell phosphoproteome.Cytomegalovirus in hematopoietic stem cell transplant recipientsAntagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.Human cytomegalovirus UL97 kinase alters the accumulation of CDK1.Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavirThe genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.How we treat cytomegalovirus in hematopoietic cell transplant recipients.Maribavir: a novel antiviral agent with activity against cytomegalovirus.Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with CytomegalovirusFunction of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.Testing the susceptibility of human herpesviruses to antivirals.Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibilityStrategies for managing cytomegalovirus in transplant recipients.The search for new therapies for human cytomegalovirus infections.Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus.The cyclin-dependent kinase ortholog pUL97 of human cytomegalovirus interacts with cyclinsOvercoming drug resistance in HSV, CMV, HBV and HCV infection.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent.Proteomic Interaction Patterns between Human Cyclins, the Cyclin-Dependent Kinase Ortholog pUL97 and Additional Cytomegalovirus Proteins.Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV.In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness.Frequent pUL27 Variations in HIV-Infected Patients.Characterising variation in five genetic loci of cytomegalovirus during treatment for congenital infection.Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens.The Interaction between Cyclin B1 and Cytomegalovirus Protein Kinase pUL97 is Determined by an Active Kinase DomainSpectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.
P2860
Q26824869-9955901F-7B10-4016-9C6E-23D0A9F08755Q27000998-4CC2909A-AC46-4F4F-AA79-F8DEA1AB6B76Q28388806-A79478EE-F0C7-409C-A72F-B659417DE5BAQ30430427-44364F9E-3F25-49D6-8258-1FEAFED551FEQ33876672-F43BA0CE-4CA0-4363-9401-7A8827B7437CQ34390310-B6FA7CE9-049A-4083-97EA-C58E597EA25BQ35270303-46EEB14D-5FD1-48B3-85B9-2FCD7F1957DEQ35590695-BC1046D3-7B65-4CB7-A854-FEA683D22806Q35596269-5EEF0487-33BE-4F6D-B888-2031BBD891FEQ35808638-F034D8E3-F503-40BE-BE85-B04F3F00C550Q35910572-C41E48A9-C8CB-4452-A0EA-67D67E3B5F5BQ35922928-0C32DF1A-D233-4BC2-8E89-867049CF5DABQ36086320-607C3F13-2ACC-41E0-95A2-71F40CFC4F59Q36523126-9EB710CD-EC8A-493E-8E2E-B66DBFF8B334Q37085793-D80C719E-7000-491C-856C-E7AA31C9E32DQ37173390-4186842F-0195-4269-8EF0-0F9B4207CB81Q37237427-7064FEED-3738-43E9-A746-CCBA7392B419Q37242251-9B8E8D1E-EE6B-4FB5-809A-534ABAA7F0FDQ37242897-ED6FD5FF-CFD1-44F5-8881-98F016DFC3BBQ37478310-0D63AB73-3A5C-4FCD-9C53-B095D9756881Q37628669-B1DD2023-A0C3-436F-9AB0-947F206A4C67Q37713957-0D86A258-3E65-48B1-A8FC-5595990332A5Q37773992-0F3DA4A4-F892-4D2A-A063-B4DDB9F43346Q37811458-98B0B1C7-3395-4662-B5B8-0EC99DB65ECBQ38067694-E1BE80EC-3FBF-4077-A38C-565266D49725Q38415861-110BD58C-834E-4DF6-A496-E0878ED565E3Q38534801-365BDD8B-33E8-4F69-AA9E-FE2661B07040Q38622013-663CEFCF-88B6-4573-AF62-FE29F39ABF7DQ38779846-37D774A2-ABF1-466B-AE23-1CB9FF3F6D75Q39155340-059EE90B-8E1C-4EDE-9078-ABED6A9A6C61Q39325580-89CCC882-57F5-40C0-B96E-5C26356A70C9Q39467030-F46D68E7-D028-4E49-9EA7-9410CC208226Q39629189-AFFC625F-26E2-4506-B68E-A847E67EC3F8Q39756225-BAACDF3A-3340-4B72-AB72-9E205C416927Q39834653-946E82B9-A8CA-47B8-8CB7-54495755DB10Q40245936-03B27025-AB88-459A-A9BE-92B39ADFDB5FQ40589966-24CFC6BE-1A92-4107-A24D-5E135094AE55Q41072110-FCD3569B-8319-4647-9F57-76784F2FF67FQ41485874-EB05A538-F5C6-4071-8ED2-F3A352E46EE2Q41722018-8B0928B6-B7CC-4CF5-A308-4F671FEC1601
P2860
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
@en
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
@nl
type
label
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
@en
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
@nl
prefLabel
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
@en
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
@nl
P2860
P356
P1476
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
@en
P2093
Sunwen Chou
P2860
P304
P356
10.1002/RMV.574
P577
2008-07-01T00:00:00Z